Showing results (431-440 of 498) with videos related to

Sort By:
Pageof 50
Leukemia|May 24, 2022
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosisAlice Nevone, Maria Girelli, Silvia Mangiacavalli, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Bortezomib, Melphalan, and Dexamethasone for Light-Chain AmyloidosisEfstathios Kastritis, Xavier Leleu, Bertrand Arnulf, et al.
Haematologica|May 27, 2014
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)Arnaud Jaccard, Raymond L Comenzo, Parameswaran Hari, et al.
Medicine|March 18, 2008
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patientsBenjamin Terrier, Arnaud Jaccard, Jean-Luc Harousseau, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
American Journal of Hematology|July 18, 2013
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemiaStéphanie Poulain, Christophe Roumier, Sylvie Galiègue-Zouitina, et al.
Plos Genetics|June 2, 2012
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic miceAnne-Pierre Morel, George W Hinkal, Clémence Thomas, et al.
Leukemia & Lymphoma|April 12, 2017
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasoneVéronique Leblond, Pierre Morel, Marie-Sarah Dilhuidy, et al.
Frontiers in Medicine|July 26, 2021
Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA NetworkAntonio Vitale, Laura Obici, Marco Cattalini, et al.
Pageof 50